These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7641897)

  • 1. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
    Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
    Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
    Franke HR; van de Weijer PH; Pennings TM; van der Mooren MJ
    Fertil Steril; 2000 Sep; 74(3):534-9. PubMed ID: 10973651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
    Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
    Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
    Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-back therapy in the treatment of endometriosis: the European experience.
    Edmonds DK
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine effects of GnRH analogue with low-dose hormone replacement therapy in women with endometriosis.
    Howell R; Dowsett M; King N; Edmonds DK
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):609-15. PubMed ID: 8548946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
    Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.
    Mäkäräinen L; Rönnberg L; Kauppila A
    Fertil Steril; 1996 Jan; 65(1):29-34. PubMed ID: 8557151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should add-back therapy for endometriosis be deferred for optimal results?
    Kiesel L; Schweppe KW; Sillem M; Siebzehnrübl E
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():15-7. PubMed ID: 8916982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
    Pierce SJ; Gazvani MR; Farquharson RG
    Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis.
    Moghissi KS; Schlaff WD; Olive DL; Skinner MA; Yin H
    Fertil Steril; 1998 Jun; 69(6):1056-62. PubMed ID: 9627292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of pelvic endometriosis with goserelin, an LHRH agonist].
    Ventruba P; Crha I; Müller P; Mlyncek M
    Ceska Gynekol; 1996 Feb; 61(1):11-6. PubMed ID: 8624587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.
    Rock JA; Truglia JA; Caplan RJ
    Obstet Gynecol; 1993 Aug; 82(2):198-205. PubMed ID: 8336864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis.
    Taskin O; Yalcinoglu AI; Kucuk S; Uryan I; Buhur A; Burak F
    Fertil Steril; 1997 Jan; 67(1):40-5. PubMed ID: 8986681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF; Gotlieb L; Casper RF
    Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
    Perry CM; Brogden RN
    Drugs; 1996 Feb; 51(2):319-46. PubMed ID: 8808170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.
    Tiitinen A; Simberg N; Stenman UH; Ylikorkala O
    J Clin Endocrinol Metab; 1994 Aug; 79(2):447-51. PubMed ID: 8045961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.